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Predictivea b s t r a c t
Microsatellite instability (MSI) is a molecular marker of a deficient mismatch repair (MMR) system and
occurs in approximately 15% of colorectal cancers (CRCs), more frequently in early than late-stage of dis-
ease. While in sporadic cases (about two-thirds of MSI-H CRCs) MMR deficiency is caused by an epige-
netic inactivation of MLH1 gene, the remainder are associated with Lynch syndrome, that is linked to
a germ-line mutation of one of the MMR genes (MLH1, MSH2, MSH6, PMS2). MSI-H colorectal cancers
have distinct clinical and pathological features such as proximal location, early-stage (predominantly
stage II), poor differentiation, mucinous histology and association with BRAF mutations. In early-stage
CRC, MSI can select a group of tumors with a better prognosis, while in metastatic disease it seems to
confer a negative prognosis. Although with conflicting results, a large amount of preclinical and clinical
evidence suggests a possible resistance to 5-FU in these tumors. The higher mutational load in MSI-H CRC
can elicit an endogenous immune anti-tumor response, counterbalanced by the expression of immune
inhibitory signals, such as PD-1 or PD-L1, that resist tumor elimination. Based on these considerations,
MSI-H CRCs seem to be particularly responsive to immunotherapy, such as anti-PD-1, opening a new
era in the treatment landscape for patients with metastatic CRC.
 2016 Elsevier Ltd. All rights reserved.Introduction
Colorectal cancer is still a major public health problem in
Western countries, representing the third most common cancer
in both women and men. Actually the 5 year-overall survival rate
approaches 65%, depending on stage of disease (90% in stage I,
15% in stage IV). Thanks to screening programs, in 2015 more than
70% of new cases underwent potentially curative resection [1].
Although traditional clinical-pathological staging remains
useful in predicting the outcome, CRC shows a significant
heterogeneity in both prognosis and response to therapy, even
within the same pathological stage.
This clinical heterogeneity may be at least in part linked to
genetic alterations that occur during the pathogenesis of CRC: in
85% of CRCs the process is driven by chromosomal alterations,
either qualitative or quantitative (chromosomal-instability path-
way), while in 15% is driven by a defective function of DNA MMR
system (microsatellite-instability pathway) [2].MSI represents a molecular hallmark of hereditary nonpolypo-
sis colorectal cancer (HNPCC), also known as Lynch syndrome
(LS), usually linked to a germ-line mutation in one of MMR genes.
Nevertheless, the majority of cases with MSI are sporadic, more
often due to an epigenetic inactivation of hMLH1 [3,4].
The prevalence of CRCs with microsatellite instability (MSI) is
different among disease stages: 15% in stage II–III (more common
in stage II) [5,6], 4–5% in stage IV [7].
The current review summarizes the clinical-pathological fea-
tures of MSI CRCs, the prognostic and predictive significance of
MSI status in early-stage and metastatic disease and the implica-
tions on new drugs development.Microsatellite instability: definition
MMR system is of pivotal importance for the rectification of
DNA sequence mismatches during DNA replication. This repair sys-
tem is mainly composed of four proteins (MLH1, MSH2, MSH6 and
PMS2) interacting together to detect mismatches and cut out them,
so that DNA polymerase and DNA ligase can resynthesize and
rebind correct DNA strand [8].
Microsatellites are short DNA motifs of 1–6 bases repeated and
distributed throughout the genome both in coding and non-coding
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ticularly prone to replication errors that are normally repaired by
the MMR system. Loss of function of one of the MMR proteins
causes a deficient MMR system leading to the accumulation of mis-
takes in microsatellites, such as insertions or deletions, which
result in a genetic instability. MSI may have an oncogenic potential
when it occurs in coding regions of genes involved in several cru-
cial cellular functions and pathways [9]. MSI is detected by PCR
amplification of specific microsatellite markers or by immunohis-
tochemical loss of expression of one of the above mentioned pro-
teins. While in LS MSI is related to germ-line mutation in one of
MMR genes (usually MLH1 or MSH2), in sporadic MSI CRCs there
is usually an epigenetic inactivation of the hMLH1 gene via methy-
lation of the gene promoter [10,11].Lynch syndrome
LS, the most frequent form of hereditary CRC, is an autosomal
dominant condition with incomplete but high penetrance, caused
by an inactivating germ-line mutation of one of the four genes
involved in the DNA MMR system (MLH1, MSH2, MSH6, PMS2).
LS is characterized by early-onset colorectal and endometrial
tumors and an increased risk of certain extra-colonic cancers,
including tumors elsewhere in the gastrointestinal tract (e.g.,
stomach, small bowel, biliary tract), in the urinary collecting sys-
tem (renal pelvis, ureter) and in the female reproductive system
(ovaries). Recent population-based studies showed a lifetime CRC
risk of about 52.2% in women and 68.7% in men and a median
age at diagnosis of 61.2 years [10–12].
Amsterdam and Bethesda criteria were developed to identify
potential LS patients candidates for genetic testing [13,14], as
shown in Tables 1 and 2 [15,16]. Nowadays, many guidelines sug-
gest two possible approaches to screen out LS: a universal one, that
is to test every patient with CRC, and a selective one, that is to test
every patient with CRC diagnosed prior than 70 plus patients diag-
nosed at older age who meet the Bethesda criteria, with the latest
approach missing more than a quarter of patients with LS (Fig. 1)
[17].
The results of immunohistochemistry and genetic testing show
excellent concordance. Nevertheless, few cases of MSI cannot be
detected by immunohistochemistry because missense mutationsTable 1
Bethesda revised guidelines for Lynch syndrome related CRC.
Tumors from individuals should be tested for MSI in the following situations:
1. CRC diagnosed in a patient who is less than 50 y.o
2. Presence of synchronous, metachronous CRC or other Lynch Syndrome related tum
pelvis, biliary tract and brain tumors, small bowel cancers, sebaceous gland adenomas
3. CRC with the MSI-H histology diagnosed in a patient who is less than 60 y.o (prese
differentiation or medullary growth pattern)
4. CRC diagnosed in a patient with one or more first-degree relatives with Lynch Syn
5. CRC diagnosed in a patient with two or more 1st or 2nd degree relatives with Lyn
Adapted Ref. [15]
Table 2
Amsterdam II criteria.
At least three relatives must have cancer associated with Lynch Syndrome (colorecta
should be present:
– One must be a first-degree relative of the other two
– At least two successive generations must be affected
– At least one relative with cancer associated with Lynch Syndrome should be diag
– FAP should be excluded in the CRC cases
– Tumors should be verified by pathological examination
Adapted Ref. [16].can lead to a dysfunctional protein, which is dismantled with loss
of antigenicity [18,19].
The first proposed panel of MSI markers consisted of two
mononucleotides (BAT-25, BAT-26) and three di-nucleotides
(D2S123, D5S346, and D17S250) [20]. A new expert consensus rec-
ommend the use of a panel of 5 quasi-monomorphic mononu-
cleotide repeats (BAT-25, BAT-26, NR21, NR24 and NR27),
characterized by a constant number of nucleotide repeats and an
identical size between individuals, unlike most microsatellites
are polymorphic [15]. CRCs can be classified into microsatellite
instability-high (MSI-H), and microsatellite instability-low (MSI-
L), depending on the percentage of loci with MSI. In particular, a
MSI-H phenotype is defined by the presence of at least two unsta-
ble markers among the 5 analyzed (orP30% of unstable markers if
a larger panel is used). Conversely, most of the sporadic CRCs are
designated as microstallite-stable (MSS), because they show chro-
mosomal instability and a lack of MSI features [21].
With immunohistochemistry it should be considered that MMR
proteins PMS2 and MSH6 cooperate with MLH1 and MSH2 respec-
tively and their expression closely depends on the binding to the
major partner (i.e. MLH1 and MSH2). Therefore, loss of expression
of MSH2 is frequently associated with loss of expression of MSH6
and this pattern is highly suggestive of MSH2 germ-line mutation.
Similarly, loss of expression of MLH1 is frequently associated with
loss of expression of PMS2 and this pattern may results either from
MLH1 germ-line mutation or from acquired somatic hypermethy-
lation of the MLH1 gene promoter. Germ-line mutations of MSH6
and PMS2 are generally associated with isolated loss of expression
of MSH6 and PMS2 protein respectively [22].Clinical-pathological features
From a clinical point of view, MSI-H CRCs are diagnosed at a
younger age, with a predominance in the right colon, frequently
raised from sessile serrated adenoma and are diagnosed at an ear-
lier stage as compared to MSS CRCs, most commonly in stage II
[23,24]. Moreover, as opposed to LS cases, sporadic CRCs are
characterized by older age at diagnosis and are more often associ-
ated with female sex and cigarette smoking [25–27].
Histologically, there are some peculiarities that may suggest the
MSI status, beyond IHC or genetic testing. A great production ofours, regardless of age (endometrial, stomach, ovarian, pancreas ureter and renal
and keratoacanthomas as seen in Muir-Torre syndrome)
nce of tumor-infiltrating lymphocytes, Chron’s-like reaction, mucinous/signet-cell
drome-related cancers, with one of the cancers diagnosed before 50 y.o
ch Syndrome related cancers regardless of age
l, endometrium, small bowel, ureter or renal-pelvis); all of the following criteria
nosed before age 50
Fig. 1. The diagnostic alghorithm for Lynch syndrome: the selective approach [13].
Table 3
Summary of results of studies with 5FU-based chemotherapy in MSI-H CRCs.
References Stage Chemotherapy regimen Results
[55] III 5FU-LEV Benefit
[54] III 5FU-based Benefit
[57] IV 5FU-FO Benefit
[3] II-III 5FU-FO Detriment
[59] II-III 5FU-based/5FU-LEV None
[36] All 5FU-based None
[52] All 5FU-based None
[58] All 5FU-based None
[53] II-III 5FU-based None
[74] II-III 5FU-based None
[62] II-III 5FU-FO Detriment
[40] All 5FU-based None
[41] II-III 5FU-based Benefit in LS
[42] II-III 5FU-FO Benefit
[65] II-III 5FU-FO Benefit in stage III
Abbreviations: FO, folinic acid; 5-FU, 5-fluorouracil; LEV, Levamisol. Adapted Ref. [8].
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within different percentage of tumour area. Also signet-ring cell
differentiation, with intracytoplasmic filling with mucin, causing
lateral dislocation of the nucleus, is frequently observed, coexisting
or not with extracellular mucin. Oftentimes MSI-H CRCs show poor
differentiation, with a peculiar incidence of medullary carcinoma, a
rare histotype, characterised by sheets of cells with vesicular nuclei
and cytoplasmatic eosinophilia [28–30].
Important lymphocytes infiltration, even with a Crohn’s like
reaction, is prominent in MSI CRCs. This is due to the lack of
MMR system with the consequent accumulation of frame-shift
mutations that causes the transcription and translation of peptides
with altered amino acid sequences (neo-antigens), that are pre-
sented by HLA class I and are recognized by cytotoxic T cells
(CTL) [31,32]. Tumor-infiltrating lymphocytes could be divided
into stroma-infiltrating lymphocytes (SIL) and intra-tumor cell
infiltrating-lymphocytes (ITCIL), that lie beyond the basal mem-
brane of the tumour cells. MSI-H CRCs show a severe infiltration
of ITCIL, that are antigen-restricted cytotoxic T-lymphocyte (CD8
+), with no difference between LS and sporadic MSI-H CRCs [33].
In the study by Tougeron et al. the number of frameshift mutations
and their presence in specific target genes (ASTE1/HT001, HNF1A
and TCF7L2) correlates to the number of infiltrating CTL. Notably,
neo-antigens are presented by antigen presenting cells (APC) also
to CD4+ T lymphocyte, that are responsible for the secretion of
cytokines that enhance and sustain the cytotoxic activity of CTL,
mainly depending on the Th1 polarisation [28,34,35].
From a molecular point of view the MSI-H status could be sus-
pected also by different mutation status in two oncogenes. BRAF
and KRAS are two mutually exclusive mutated oncogenes that
encode for serine/threonine kinase leading to stimulation of the
mitogen-activated protein kinase pathway (RAS-RAF-MEK-ERK)
[36]. BRAF V600E mutations can be useful to rule out LS, because
they frequently occur in sporadic MSI CRCs, caused by MLH1 pro-
moter methylation, especially in C-region, while rarely can be
detected in LS-related CRCs, except for cases associated with
PMS2 germ-line mutation. By contrast, KRAS mutations (in codons
12 or 13) are inversely correlated with MSI-H status [37–39].Interestingly, in a recent work Stadler et al. demonstrated that a
multigene NGS tumor profiling panel can reliably discriminate
between deficient-MMR (dMMR) and proficient-MMR (pMMR)
CRCs on the basis of a mutational load cut-off, providing simulta-
neously information about mutational status of RAS, BRAF and
other genes [40].
Prognostic role of MSI in early and metastatic disease
MSI-H CRCs have peculiar clinical features and a better progno-
sis compared to MSS tumors. In some reports this survival advan-
tage seems to be independent of tumour stage [41,42], whereas in
others seems to be confined to stage II [43] or stage III [44], but
these data are likely confounded by the effect of adjuvant
chemotherapy (Table 3) adapted Ref. [8].
A meta-analysis evaluated 1277 MSI-H stage I–IV CRC patients
from a total of 32 eligible studies. The authors found that the effect
of MSI on prognosis was independent from patient selection and
was maintained in both the early and advanced setting, with a
35% reduction in the risk of death (HR 0.65, 95% CI 0.59–0.71). This
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with 5-FU-based chemotherapy and the benefit was maintained
when restricting the analysis to clinical trial participants [45].
Afterwards, data from a meta-analysis by Guastadisegni et al.
confirmed the association between MSI and favourable prognosis
in 31 eligible studies providing overall survival (OS) data from
1972 stage I–IV MSI-H patients [46]. The better outcome was found
in terms of OS, disease-specific survival (DSS) and disease-free sur-
vival (DFS). Subsequent clinical trials confirmed that dMMR
tumors have a significantly reduced recurrence rate as compared
to pMMR ones [47,48].
In a retrospective analysis of the QUASAR study, that included
1913 CRC patients who were randomly assigned to receive or not
adjuvant treatment with 5-FU/LV, the prognostic value of MMR
was similar in the presence and absence of chemotherapy. Sup-
porting these data, in the 5-FU control arm of the PETACC3 trial
in more than 600 stage II–III patients, the good prognostic effect
of MSI remained significant (p = 0.0077) [48,49].
Moreover, in a multicentre retrospective analysis of 521 stage
I–III MSI-H CRCs, bowel obstruction, stage T4 and vascular emboli
were found to be independent predictors of poor DFS in multivari-
ate analysis, thus highlighting the importance of the screening for
vascular emboli to guide the decision whether or not to offer adju-
vant chemotherapy in these patients [50].
Another interesting point is the role of BRAF mutations, whose
relationship with MMR status in early-stage disease is still a matter
of debate.
In a post-hoc analysis of the PETACC3 trial the impact of BRAF
mutational status on OS was restricted to MSI-L and MSS tumors,
while no prognostic significance was shown in the 190 MSI-H
tumors [49]. This hypothesis was further corroborated by Samow-
itz et al. in a large US database: in 900 patients with stage I–IV dis-
ease, the BRAF V600E mutation did not affect the excellent
prognosis of MSI tumors [51].
Focusing on this topic, Lochhead et al. evaluated a large US
database and suggested that patients with MSI-H/BRAFWT have
the best prognosis, while BRAF mutant tumors are associated with
the highest mortality [52]. This hypothesis was confirmed in the
CALGB 89803 adjuvant trial: in 34 patients with MSI-H/BRAFMT
tumors the prognostic role of MSI was balanced by BRAF mutation,
resulting in the same survival as patients with MSS/BRAFWT
tumors; in other words, survival was longer in patients with
MSI-H/BRAFWT disease and intermediate in patients with MSS/
BRAFWT or MSI-H/BRAFMT disease, whereas patients with MSS/
BRAFMT had the worst prognosis [53].
Therefore, collectively these data demonstrate that in early-
stage disease BRAF mutation has a negative prognostic effect in
MSS and MSI-L CRC, whereas in MSI-H tumors seem to partially
mitigate the good prognostic effect of MSI.
In metastatic setting few data about the role of MMR status are
available, mainly because of the low prevalence of MSI in stage IV,
thus supporting the hypothesis that MSI CRCs have a lower meta-
static potential [54,55].
In a series of recurrent CRCs, lower OS from diagnosis to death
(OS1) and from recurrence to death (OS2) were observed in
patients with MSI-H tumors. Of note, they also had a lower recur-
rence rate, more local and peritoneal recurrences, were less likely
to undergo curative resection and did not benefit from conversion
therapy, reflecting the intrinsic chemoresistance of these subsets of
metastatic CRCs [56].
These data were confirmed in a pooled analysis of 4 phase III
studies in first-line treatment of metastatic disease (CAIRO,
CAIRO2, COIN, FOCUS): in 153 MSI-H patients median PFS and OS
were significantly worse as compared to pMMR patients (PFS 6.2
vs 7.6 months, HR 1.33; 95% CI 1.12–1.57, p = 0.001 and OS 13.6
vs 16.8 months, HR 1.35; 95% CI 1.13–1.61, p = 0.001) [57].In an another retrospective analysis, 55 patients with dMMR
metastatic CRC were evaluated and did not appear to have
improved outcomes (OS 15.4 months, 95% CI 10.61–17.74) even
following R0/R1 metastasectomy (OS 33,8 months, 95%CI 14,5–
76,5) as compared to historical pMMR controls. In this setting,
patients with MSI-H/BRAFWT tumors had an improved overall sur-
vival when compared with MSI-H/BRAFMT tumors (17.3 vs
10.1 months; p = 0.029) [58].
Therefore, based on the above mentioned clinical data in the
metastatic setting, it seems likely that MSI can have a negative
prognostic role and that BRAF mutation can at least in part drive
the poorer outcome observed.Predictive role of MSI in adjuvant and metastatic setting
Regarding the role of MSI in predicting chemotherapy efficacy
in early-stage CRC, a growing body of literature seems to suggest
a lack of benefit of 5-FU chemotherapy in patients with dMMR,
although the data are conflicting [5,42,59–66], as shown in Table 3
adapted Ref. [8].
Preclinical data showed that the presence of a dMMR status is
associated with resistance to 5-FU [67,68]. A pooled analysis of 5
clinical trials by Ribic and colleagues [5], in which patients with
stage II and III colon cancer were randomized to 5-FU plus levami-
sole or leucovorin versus surgery alone, demonstrated a better sur-
vival of patients with dMMR CRC treated with surgery alone and a
lack of benefit of 5-FU-based chemotherapy. These results were
confirmed in a subsequent analysis where the cases above men-
tioned were combined with those of a previous study of the same
group. In particular, in patients with stage II dMMR tumors treat-
ment was associated with reduced overall survival (HR, 2.95; 95%
CI 1.02–8.54, p = 0.04) [69].
In the QUASAR trial, chemotherapy with 5-FU plus folinic acid
compared to surgery alone improved survival in patients with
stage II CRC [70]; interestingly, recurrence rate for dMMR tumors
was half that of pMMR tumors (11% vs 26%; risk ratio [RR], 0.53;
95% CI 0.40–0.70, p < .001), but the chemotherapy efficacy did
not differ significantly by MMR status [47].
In a pooled data analysis from the ACCENT database, time-to-
relapse (TTR) and OS differ between dMMR and pMMR stage II
CRC patients treated with surgery alone (TTR, HR 0.27; 95% CI
0.10–0.75; p = 0.01; OS HR 0.27; 95% CI 0.10–0.74, p = 0.01) but this
advantage was attenuated in patients treated with 5-FU adjuvant
chemotherapy (TTR HR 0.81; 95% CI 0.55–1.19, p = 0.29; OS, HR
0.87; 95% CI 0.61–1.26, p = 0.47). The prognostic role of MSI was
confirmed also in stage III CRC patients treated with surgery alone
(TTR HR 0.59; 95% CI 0.28–1.23, p = 0.16; OS HR 0.69; 95% CI 0.35–
1.36, p = 0.28) and a significant survival benefit for 5-FU monother-
apy vs surgery alone was seen both in patients with pMMR tumors
(5-year survival rate = 71% vs 54%) and in patients with dMMR
tumors (5-year survival rate = 77% vs 59%) [71].
In another analysis by Sinicrope and coworkers, 2141 patients
with stage II and III CRC treated within randomized trials of 5-
FU-based chemotherapy were evaluated: patients with dMMR
CRC have reduced recurrence rates, delayed time to relapse, and
improved survival rates, as compared to patients with pMMR
CRC; a subset analysis suggested that any treatment benefit was
restricted to suspected germ-line versus sporadic tumors. In addi-
tion, patients with stage III dMMR CRC treated with adjuvant 5-FU
had a lower 5-year recurrence rate compared to patients receiving
surgery alone (22% vs 37%; p = 0.04) [47].
Therefore, while adjuvant 5-FU chemotherapy does not seem to
have an impact on the already good prognosis of patients with
stage II MSI-H CRC, it should be considered as an option in patients
with stage III MSI-H CRC.
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oxaliplatin added to a fluoropyrimidine (5-FU, Capecitabine) as
the current standard of care for adjuvant treatment of stage III
CRC patients [72–74].
In contrast to 5-FU, preclinical studies demonstrated that MSI
tumor cells are sensitive to oxaliplatin [75], but to date few data
with conflicting results have been published regarding the rela-
tionship between MMR status and oxaliplatin efficacy [76–78].
An analysis of patients with stage II and III CRC enrolled in
NSABP C07 trial (5-FU plus folinic acid ± oxaliplatin) and C08
(FOLFOX ± bevacizumab) showed that dMMR was associated with
an improved prognosis based on recurrence (HR 0.48, 95% CI
0.33–0.70, p < 0.0001), but was not predictive for oxaliplatin bene-
fit [79].
Conversely, in a recent update of the MOSAIC phase III trial,
comparing bolus/infusional fluorouracil plus leucovorin (LV5FU2)
with LV5FU2 plus oxaliplatin (FOLFOX4), dMMR was an indepen-
dent prognostic factor (HR 2.02; 95% CI 1.15–3.55, p = 0.014) and
HRs for DFS and OS benefit in the FOLFOX4 arm were 0.48 (95%
CI, 0.20–1.12) and 0.41 (95% CI 0.16–1.07), respectively, in patients
with stage II and III dMMR CRC [6].
To complicate this issue further, in an analysis of the NO147
trial (a phase III trial comparing FOLFOX versus FOLFOX plus
Cetuximab in stage III KRAS wild-type CRC), favorable DFS was
observed for dMMR proximal tumors and any survival benefit
was lost in distal and N2 tumors, suggesting that the predictive
role of MMR status may depend on tumor location and nodal status
[80].
Furthermore, in the AGEO study a large dataset of 433 dMMR
stage II and III CRCs treated with surgery alone or surgery plus
adjuvant chemotherapy consisting of fluoropyrimidine plus or
minus oxaliplatin was analyzed [81]. As compared to surgery
alone, adjuvant oxaliplatin-based chemotherapy improved DFS,
contrary to fluoropyrimidine alone, with a statistically significant
benefit in multivariate analysis limited to stage III tumors and to
sporadic rather than LS cases.
Taken together these results, although controversial and deriv-
ing from retrospective analysis, seem to suggest the ability of
oxaliplatin to overcome the detrimental effect of fluoropyrimidine
monotherapy in dMMR CRCs, with the greatest benefit likely lim-
ited to certain subgroups (stage III, proximal location, N1 disease,
sporadic cases).
In addition, a recent work by Dalerba and colleagues demon-
strated that loss of CDX-2 identified a distinct phenotype of stage
II CRC with worse prognosis and which seems to benefit from adju-
vant chemotherapy [82]. To add complexity to this intricate sce-
nario, MSI-H tumors appear to be characterized by an
enrichment in CDX-2 negative tumors as compared to MSS ones;
the relationship between these two factors deserve further evalu-
ations, but it seems counterintuitive the correlation between a fac-
tor associated with good prognosis and probably resistance to 5-FU
such as MSI with the CDX-2 negative status, which, on the con-
trary, confers a bad prognosis and a benefit from adjuvant
chemotherapy.
Another crucial point concerns the predictive role of MSI in
locally advanced rectal cancer (LARC) treated with neo-adjuvant
fluoropyrimide-based chemo-radiation. Recently, de Rosa and col-
leagues retrospectively analyzed a series of 62 patients with germ-Table 4
Summary of ongoing clinical trials with anti-PD1 (±anti CTLA-4) in metastatic MSI-H CRC
Trial identifier Drug/s
KEYNOTE-164 (NCT02460198) Pembrolizumab
KEYNOTE-177 (NCT02563002) Pembrolizumab
CHEKMATE-142 (NCT02060188) Nivolumab, Ipilimumabline dMMR rectal cancer, demonstrating a striking 27.6% of patho-
logical complete response rate and outstanding stage-adjusted sur-
vival rates. Identification of a dMMR rectal cancers should not only
trigger confirmatory germ-line testing, but could also influence the
extent of surgical resection that should take into account several
factors such as the presence of a synchronous colonic lesion, the
tumor height, the clinical stage and the need for pelvic irradiation
[83].
In contrast to early-stage disease, very few studies have ana-
lyzed the predictive role of MMR status in the metastatic setting,
since only 4% of stage IV CRCs are MSI-H.
In a meta-analysis published by Des Guetz and colleagues,
among 964 patients, 91 of whom had MSI-H tumors, no benefit
of chemotherapy in terms of response rate for MSI-H compared
with MSS tumors was found [84].
These results could therefore have implications especially in the
management of liver metastases potentially eligible to surgery,
where objective response could convert to surgery patients with
initially inoperable disease. Since neo-adjuvant chemotherapy rep-
resents the standard of care, knowledge of MMR status, along with
RAS and BRAF mutational status, could inform and guide clinical
decision making also in this setting.Immunotherapy in MSI colorectal cancers
As already stated, MSI-H CRCs manifest an important inflamma-
tory response against which cancer cells line up several immune-
escape strategies. For instance, beyond CD4+ and CD8+ T-cells
the tumour microenvironment promotes the accumulation of
Tregs that aim to turn the immune response towards cancer cells
with the secretion of TGFb and IL10 [32,85,86]. Moreover, there
is an upregulation of inhibitory molecules such as checkpoint inhi-
bitors (PD1, PDL1, CTLA4, lymphocyte-activation gene 3 and IDO)
that, as well as Tregs, counterbalance the activation of the immune
system with the classic ‘‘exhaustion” phenotype of TILs. The upreg-
ulation of immune checkpoints inhibitors is a consequence of the
response to cytokines, like INFc, that are part of the intra-
tumoral immune activation. The consequence of this negative con-
trol is the inability of the immune system to eradicate cancer cells
[87,88].
To overcome this obstacle, on the basis of a phase I trial evalu-
ating anti PD-1 antibody therapy in patients with treatment-
refractory solid tumours, in which only one case between CRCs,
that turned out to be MSI, showed a complete durable response,
Le et al. published a phase II study evaluating Pembrolizumab in
patients with dMMR and pMMR CRC and a cohort of patient with
neoplasms other than colorectal characterised by MMR deficiency
[89,90]. The study reached the primary end point, showing a strik-
ing immune-related and RECIST objective response rate of 40% (4
of 10 patients), a disease control rate of 90% and an immune-
related PFS rate at 20 weeks of 78% (7 of 9 patients) in the cohort
of dMMR CRCs. Conversely, in the cohort of pMMR CRCs no
immune-related and RECIST objective response rate were observed
and the immune-related PFS rate at 20 weeks was 11%. Of note, all
6 patients with sporadic dMMR CRCs had and objective response,
whereas only 3 of 11 (27%) patients with LS CRCs had a response.
One explanation could be that germ-line dMMR CRCs had a lower
number of frameshift mutations compared to the sporadic coun-.
Phase Setting References
II Pre-treated [91]
III 1-st line [92]
I/II Pre-treated [93]
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genesis of these 2 types of CRC [34].
To better clarify the potency of this new approach, a phase II
(KEYNOTE-164) and a phase III (KEYNOTE-177) clinical trials eval-
uating Pembrolizumab in CRCs with MSI or MMR deficiency are
ongoing [91,92]. Another trial (CHECKMATE-142) testing Nivolu-
mab (anti PD-1) monotherapy and the association between Nivolu-
mab and Ipilimumab (anti-CTLA-4 antibody) in MSI CRCs is
ongoing [93] (Table 4).
Conclusions and future perspectives
Although LS is the most frequent cause of heritable CRC, it is
still frequently underrecognised and underdiagnosed. In this con-
text, it is of paramount importance to have widely available and
easy-to-perform tests, in order to select patients who deserve fur-
ther evaluation with a confirmatory germ-line testing and to offer
the appropriate management to the patients and their relatives.
As regard early-stage CRC, MSI is a clear prognostic factor, espe-
cially in stage II, and a predictive marker of resistance to 5-FU,
although literature data on this topic are conflicting. Despite this,
some grey areas persist, in which there is room for improvement
and for a shared decision making with the patients, for example
in ‘high risk’ MSI-H stage II disease.
Differently from stage II, in stage III CRC it is unlikely that the
MSI status would influence the choice of treatment (FOLFOX or
XELOX). Nevertheless, a relevant and practical question is: should
we treat with 5-FU or Capecitabine alone a patient with stage III
MSI-H CRC not candidate to receive oxaliplatin?
In metastatic disease, the active immune microenvironment of
MSI-H tumors makes these patients good candidate for enrollment
in clinical trials with immune targeted therapies such as Nivolu-
mab or Pembrolizumab, though only few patients have MSI-H
metastatic CRC.
In conclusion, MSI CRC is an heterogeneous group of sporadic
and heritable diseases which may behave differently, according
to other characteristics (such as BRAF mutational status). MSI stud-
ies are difficult because of the low incidence of this characteristic,
in different stages of the disease, with different standard treat-
ments over time. In the future, it would be desirable to develop
worldwide collaboration to obtain a sufficient number of patients
to shed light on many unanswered questions. Furthermore, given
the unprecedented outcome achieved with immunotherapy that
would probably represent a ‘game changer’ in the management
of metastatic MSI-H CRCs, clinical trials in other settings (neoadju-
vant or adjuvant) are eagerly awaited.
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